Vivek Subbiah: Key Recommendations for structuring Molecular Tumour Boards in clinical practice
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a LinkedIn post about recent paper he and his colleagues authored:
“Hot off the press!
The ESMO – European Society for Medical Oncology Precision Oncology Working Group has unveiled key ‘Recommendations for structuring Molecular Tumour Boards (MTBs) in clinical practice’, now published in ESMO’s flagship journal Annals of Oncology Annals of Oncology.
Highlights:
– A structured list for MTB quality and workflow
– Tailored recommendations for local adaptation
– Quality indicators for benchmarking MTBs
Honored to be a part of this amazing working group with Benedikt Westphalen, Giuseppe Curigliano, Fabrice Andre, David Solit, Christophe Massard et al.”
ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
Authors: C.B. Westphalen, Vivek Subbiah et al.
More posts featuring Vivek Subbiah on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023